Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05919511 · ClinicalTrials.gov registry record
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
A clinical trial of cGVHD, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 20
- Study locations
NCT05919511: Recruiting study of cGVHD, sponsored by Incyte Corporation.
NCT05919511 is a study of cGVHD that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 1,500 participants, above the 24-participant average among 3 other cGVHD trials with a reported enrollment target (6150% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05919511, a study of cGVHD, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Conditions Studied
Interventions
- OTHER Non-Interventional
Study Locations (20)
Illinois
- Northwestern University - Chicago
- Rush University Medical Group - Chicago
- The University of Chicago - Chicago
- Loyola University Medical Center - Maywood
Florida
- Mayo Clinic Jacksonville - Jacksonville
- AdventHealth Orlando - Orlando
- Moffit Cancer Center - Orlando
California
- City of Hope - Duarte
- USC Norris Comprehensive Cancer Center - Los Angeles
Georgia
- Emory University - Atlanta
- Georgia Cancer Center - Augusta
Alabama
- University of Alabama Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
Colorado
- University of Colorado - Aurora
Kansas
- The University of Kansas Clinical Research Center - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2027-10-15 |
What NCT05919511 shows while recruiting
NCT05919511 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 24-participant average among 3 other cGVHD trials with a reported enrollment target (6150% higher).
The record links to 1 condition, with cGVHD appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional is the first listed.
NCT05919511 names 20 study sites across 13 states, led by Illinois, Florida, California.
Frequently Asked Questions
What is clinical trial NCT05919511 about?
NCT05919511 is a clinical study titled "Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease". The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
What is the current status of trial NCT05919511?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2023-08-01. Estimated completion is 2027-10-15.
What conditions does trial NCT05919511 study?
This clinical trial studies the following conditions: cGVHD.
What interventions are being tested in trial NCT05919511?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT05919511?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05919511 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for cGVHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
-
Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
ACTIVE NOT RECRUITING · NA
-
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI